ESSA Pharma

Developing the
Next Generation of
Treatments for
Prostate Cancer

About ESSA

ESSA is a clinical-stage pharmaceutical company focused on developing novel therapies for the treatment of prostate cancer. ESSA’s lead clinical candidate, EPI-7386, represents a new approach to disrupting androgen receptor signaling pathway, the primary driver of prostate cancer growth.

Learn More


ESSA’s investigational therapies are designed to disrupt the androgen receptor (AR) signaling pathway, the primary pathway that drives prostate cancer growth, and prevent AR activation through selective binding to the N-terminal domain, a region of the AR that is not currently targeted by other therapies.

Events &

Clinical Trials

ESSA is currently conducting a monotherapy Phase 1 open-label clinical trial with EPI-7386 for patients with castration-resistant prostate cancer (CRPC).

ESSA is also conducting a Phase 1/2 study of EPI-7386 in combination with enzalutamide in patients with metastatic CRPC who have not yet been treated with second-generation antiandrogen therapies.

Learn More